-
Mashup Score: 21Insights into the etiology of Castleman disease - 3 day(s) ago
In this issue of Blood, Chan et al report on in-depth studies of identical twins with idiopathic multicentric Castleman disease (iMCD), which provides a un
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
Chairs : Claire Harrison, Andreas Hochhaus, Ruben Mesa March 7-9, 2025 – Vienna, Austri Chairs: Claire Harrison, Andreas Hochhaus, Ruben Mesa ESH How to Diagnose and Treat meetings are disease-specific meetings that address state-of-the-art diagnostic and clinical management. They are based on the presentation and analysis of real clinical cases. Voting technology is used as a self-evaluation tool and to increase scientific interaction. This meeting will be of interest to: • Senior biologists and clinician
Source: www.esh.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9
The presence of BRAF mutation in hematological malignancies, excluding Hairy cell leukemia, and its significance as a driver mutation in myeloid neoplasms (MNs) remains largely understudied. This r…
Source: www.tandfonline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 22
There is a need to understand and define disease modification in myelofibrosis. This review examines the latest clinical data of targeted therapies for myelofibrosis and proposes a definition of dise…
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 23Royals rookie Hill thriving after beating cancer - 11 day(s) ago
DETROIT — Royals rookie left-hander Tim Hill looked in the mirror and hardly recognized himself. A skeleton, he thought. He needed to take a photo, perhaps just to remind himself one day of this trying time in his life.It was the fall of 2015, and Hill was near completion of
Source: www.mlb.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 29Moving toward disease modification in polycythemia vera - 11 day(s) ago
Polycythemia vera is a BCR-ABL1–negative myeloproliferative neoplasm that reduces life expectancy through thrombosis, marrow failure, and transformation to leuk
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 34Chernobyl and Biology: Dual Degree Prompts Alumni Award Winner to Pivot | School of Molecular & Cellular Biology | UIUC - 23 day(s) ago
Congratulations to Dr. Mesa, a 2024 College of Liberal Arts & Sciences Distinguished Alumni Award Recipient!
Source: mcb.illinois.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 29Hope for a Rare Disease: Myelofibrosis - The Bloodline with LLS - 1 month(s) ago
“If you have a rare disease, it’s not rare to you.” In this episode, Dr. Naveen Pemmaraju of MD Anderson Cancer Center in Houston, TX, sheds light on the latest treatment advancements for myelofibrosis. The pace of scientific discovery for rare diseases is moving at a fast rate, resulting in better outcomes for myelofibrosis patients.
Source: thebloodline.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Featuring an interview with Prof Naveen Pemmaraju, including the following topics: Case: A woman in her mid 20s with classic blastic plasmacytoid dendritic cell neoplasm (BPDCN) who responded to combination hyper-CVAD/venetoclax (0:00) Defining and diagnosing BPDCN (5:17) Presentation, prevention and management of capillary leak syndrome (7:56) Targeting CD123 in BPDCN (12:53) Case: A man in his early 70s with TET-mutated BPDCN who had a complete response to tagraxofusp (14:21) Selection of CD123-targeted therapy for patients with BPDCN (20:05) Case: A man in his mid 60s who had a complete response to pivekimab sunirine (27:04) Future directions in the treatment of BPDCN (28:55)
Categories: General Medicine News, Hem/OncsTweet
Insights into the etiology of #Castleman disease | Blood | American Society of Hematology | @DavidFajgenbaum @CureCastleman #Castleman #RareDisease @BloodJournal @mtmdphd #CastlemanStrong https://t.co/OMq4mzFkxA